NovoCure Limited
HealthcareNASDAQ:NVCR · NASDAQ Global Select
+$0.07 today
Vol 0.99M · Avg 1.50M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-40.0%
avg -38.8%
ROIC
-25.9%
avg -17.4%
ROA
-16.9%
avg -16.9%
Analysis
ROA is currently the strongest return metric at -16.9% versus its period average of -16.9%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
William F. Doyle | Executive Chairman | $1.78M | — | 64 | $400,284.00 | 0.35% |
Christoph Brackmann | Chief Financial Officer | $1.16M | — | 52 | $182,842.00 | 0.16% |
Uri Weinberg | Chief Innovation Officer & Chief Medical Officer | $1.16M | — | 47 | $267,190.00 | 0.23% |
Frank Leonard | Chief Executive Officer & Director | $974,316.00 | — | — | $459,520.00 | 0.40% |
Mukund Paravasthu | Chief Operating Officer | $965,560.00 | — | 56 | $72,832.00 | 0.06% |
Michael Puri | Chief Human Resources Officer | $932,882.00 | — | 57 | $201,322.00 | 0.17% |
Barak Ben Arye | General Counsel | $796,075.00 | — | 49 | $242,453.00 | 0.21% |
Adam Daney | Head of Investor Relations | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
4
$1.23M
Sells
22
$3.21M
Net Sentiment
$1.98M
Net selling
Most Active
Leonard Frank X
4 transactions
1–10 of 26
Analysis
Insiders reported 4 buys worth $1.23M and 22 sells worth $3.21M over the last 12 months. That adds up to net selling of $1.98M. Leonard Frank X was the most active insider with 4 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | +125.2% | +19.3% (13yr)3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Recent growth has been strongest in Revenue at +125.2% over three years. Forward estimates point to Revenue at +19.3% (13yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Establishment Labs Holdings Inc.
NASDAQ:ESTA
$2.42B
Neogen Corporation
NASDAQ:NEOG
$1.98B
Pulse Biosciences, Inc.
NASDAQ:PLSE
$1.69B
STAAR Surgical Company
NASDAQ:STAA
$1.41B
Teladoc Health, Inc.
NYSE:TDOC
$1.32B
BioLife Solutions, Inc.
NASDAQ:BLFS
$1.28B
Kestra Medical Technologies, Ltd.
NASDAQ:KMTS
$1.22B
Azenta, Inc.
NASDAQ:AZTA
$1.04B
Evotec SE
NASDAQ:EVO
$966.11M
Upstream Bio, Inc.
UPB
$331.96M
Who manages NVCR?
NovoCure Limited (NVCR) lists 8 active executives. The top listed executive is Uri Weinberg, Chief Innovation Officer & Chief Medical Officer.
Are NVCR insiders buying or selling?
Recent insider activity shows net buying of $38.62M.
Explore More
Continue the stock analysis
Jump to another research area for this company.